A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimers Disease (MissionAD1)
MissionAD1: A 24-month Efficacy and Safety Study in Subjects with Early Alzheimer's Disease
Sponsor: EISAI
Enrolling: Male and Female Patients
Study Length: 24 Months
IRB Number: AAAR2556
U.S. Govt. ID: NCT02956486
Contact: Evelyn D. Dominguez: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information: The name of this trial is MissionAD. This is a 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (AD), includingmild cognitive impairment (MCI) due to AD, known as Prodromal AD, and the early stages of mild AD.The study will be conducted to evaluate the efficacy and safety of E2609, whose proposed international nonproprietary name is elenbecestat.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Do you have mild cognitive impairment due to Alzheimer's disease or mild AD dementia? Yes No
Do you have a study partner able to support your partiipation for the duration of the study? Yes No
Have you had a stroke or mini stroke in the past 12 months? Yes No
Do you have a history of seizures within the past 5 years? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Evelyn D. Dominguez